A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 88, Issue 2, 2013, Pages 163-169

  Alicandro, G ^a   Faelli, N ^a   Gagliardini, R ^b   Santini, B ^c   Magazzu G ^d   Biffi, A ^a   Rise P ^a   Galli, C ^a   Tirelli, A S ^e   Loi, S ^a   Valmarana, L ^a   Cirilli, N ^b   Palmas, T ^c   Vieni, G ^d   Bianchi, M L ^f   Agostoni, C ^a   Colombo, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Cystic fibrosis; Docosahexaenoic acid; Plasma fatty acids; Randomised clinical trial; Supplementation

Indexed keywords

ALPHA TOCOPHEROL; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; INTERLEUKIN 8; PLACEBO; RETINOL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BODY COMPOSITION; BODY MASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRANSAMINASEMIA; LOADING DRUG DOSE; LUNG FUNCTION; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKINFOLD THICKNESS; SUPPLEMENTATION; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ALPHA-TOCOPHEROL; BODY COMPOSITION; BONE DENSITY; C-REACTIVE PROTEIN; CHILD; CYSTIC FIBROSIS; DOCOSAHEXAENOIC ACIDS; FEMALE; HUMANS; INTERLEUKIN-8; MALE; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN A;

ALGAE;

EID: 84875803960     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.10.002     Document Type: Article

References (40)

1. Colombo C., Bennato V., Costantini D., Valmarana L., Daccò V., Zazzeron L., Ghisleni D., Bruzzese M.G., Scaglioni S., Riva E., et al. Dietary and circulating polyunsaturated fatty acids in cystic fibrosis: are they related to clinical outcomes?. J Pediatr Gastroenterol. Nutr. 2006, 43:660-665.
2. Risé P., Volpi S., Colombo C., Padoan R.F., D'Orazio C., Ghezzi S., Melotti P., Bennato V., Agostoni C., Assael B.M., et al. Whole blood fatty acid analysis with micromethod in cystic fibrosis and pulmonary disease. J. Cyst. Fibros. 2010, 9:228-233.
3. Roulet M., Frascarolo P., Rappaz I., Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur. J. Pediatr. 1997, 156:952-956.
4. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., Weed D.A., Gelrud A., Regan M.M., Laposata M., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 2004, 350:560-569.
5. Strandvik B., Svensson E., Seyberth H.W. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot. Essent. Fatty Acids 1996, 55(6):419-425.
6. Al-Turkmani M.R., Freedman S.D., Laposata M. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77(5-6):309-318.
7. Strandvik B. Fatty acid metabolism in cystic fibrosis. Prostaglandins Leukot. Essent. Fatty Acids 2010, 83(3):121-129.
8. Guilbault C., Wojewodka G., Saeed Z., Hajduch M., Matouk E., De Sanctis J.B., Radzioch D. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am. J. Respir. Cell. Mol. Biol. 2009, 41(1):100-106.
9. Iuliano L., Monticolo R., Straface G., Zullo S., Galli F., Boaz M., Quattrucci S. Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. Am. J. Clin. Nutr. 2009, 90(3):477-484.
10. Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 2007, 25:101-137.
11. Bannenberg G., Serhan C.N. Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim. Biophys. Acta 2010, 1801(12):1260-1273.
12. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc. Natl. Acad. Sci. USA 1999, 96(24):13995-14000.
13. Oliver C., Jahnke N. Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst. Rev. 2011, (8):CD002201.
14. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., Crapo R., Enright P., van der Grinten C.P., Gustafsson P., et al. ATS/ERS Task Force. Standardisation of spirometry. Eur. Respir. J. 2005, 26(2):319-338.
15. Kuczmarski R.J., Ogden C.L., Guo S.S., Grummer-Strawn L.M., Flegal K.M., Mei Z., Wei R., Curtin L.R., Roche A.F., Johnson C.L. CDC growth charts for the United States: methods and development. Vital Health Stat. 2002, 11(246):1-190.
16. Lohman T.G., Roche A.F., Martorell R. Anthropometric Standardization Reference Manual 1988, Human Kinetics, Champaign, IL.
17. Frisancho A.R. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am. J. Clin. Nutr. 1981, 34(11):2540-2545.
18. Lai H.J., Shoff S.M. Classification of malnutrition in cystic fibrosis: implications for evaluating and benchmarking clinical practice performance. Am. J. Clin. Nutr.. 161e6 2008, 88.
19. Stallings V.A., Stark L.J., Robinson K.A., Feranchak A.P., Quinton H. Clinical practice guidelines on growth and nutrition subcommittee; Ad Hoc working group. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J. Am. Diet. Assoc.. 832e9 2008, 108.
20. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., Coquillette S., Fieberg A.Y., Accurso F.J., Campbell P.W. 3rd; Macrolide study group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290(13):1749-1756.
21. Marangoni F., Angeli M.T., Colli S., Eligini S., Tremoli E., Sirtori C.R., Galli C. Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout. Biochim. Biophys. Acta 1993, 1210(1):55-62.
22. Keen C., Olin A.C., Eriksson S., Ekman A., Lindblad A., Basu S., Beermann C., Strandvik B. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 2010, 50(5):537-544.
23. Van Biervliet S., Devos M., Delhaye T., Van Biervliet J.P., Robberecht E., Christophe A., Oral D.H.A. supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot. Essent. Fatty Acids 2008, 78(2):109-115.
24. Lloyd-Still J.D., Powers C.A., Hoffman D.R., Boyd-Trull K., Lester L.A., Benisek D.C., Arterburn L.M. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 2006, 22(1):36-46.
25. Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Boulat O., Hug C., Pilet M., Roulet M. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin. Nutr. 2006, 25(3):418-427.
26. Katz D.P., Manner T., Furst P., Askanazi J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition 1996, 12(5):334-339.
27. Kurlandsky L.E., Bennink M.R., Webb P.M., Ulrich P.J., Baer L.J. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr. Pulmonol. 1994, 18(4):211-217.
28. Henderson W.R., Astley S.J., McCready M.M., Kushmerick P., Casey S., Becker J.W., Ramsey B.W. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J. Pediatr. 1994, 124(3):400-408.
29. Lawrence R., Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 1993, 342(8869):465-469.
30. Christophe A., Robberecht E., De Baets F., Franckx H. Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. Ann. Nutr. Metab. 1992, 36(5-6):304-312.
31. Jumpsen J.A., Brown N.E., Thomson A.B., Paul Man S.F., Goh Y.K., Ma D., Clandinin M.T. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J. Cyst. Fibros. 2006, 5(2):77-84.
32. De Vizia B., Raia V., Spano C., Pavlidis C., Coruzzo A., Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J Parenter Enteral Nutr. 2003, 27(1):52-57.
33. Al-Turkmani M.R., Andersson C., Alturkmani R., et al. A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA. J. Lipid Res. 2008, 49:1946-1954.
34. Döring G., Elborn J.S., Johannesson M., et al. Clinical trials in cystic fibrosis. J. Cyst. Fibros. 2007, 6:85-99.
35. Raederstorff D., Moser U. Influence of an increased intake of linoleic acid on the incorporation of dietary (n-3) fatty acids in phospholipids and on prostanoid synthesis in rat tissues. Biochim. Biophys. Acta 1992, 1165:194-200.
36. Beharry S., Ackerley C., Corey M., Kent G., Heng Y.M., Christensen H., Luk C., Yantiss R.K., Nasser I.A., Zaman M., et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292(3):G839-G848.
37. Bianchi M.L., Romano G., Saraifoger S., Costantini D., Limonta C., Colombo C. BMD and body composition in children and young patients affected by cysticfibrosis. J Bone Miner Res. 2006, 21:388-396.
38. Lucidi V., Bizzarri C., Alghisi F., Bella S., Russo B., Ubertini G., Cappa M. Bone and body composition analyzed by Dual-energy X-ray Absorptiometry (DXA) in clinical and nutritional evaluation of young patients with Cystic Fibrosis: a cross-sectional study. BMC Pediatr. 2009, 28(9):61.
39. Gronowitz E., Mellström D., Strandvik B. Serum phospholipid fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis. Br. J. Nutr. 2006, 95(6):1159-1165.
40. Nauroth J.M., Liu Y.C., Van Elswyk M., et al. Docosahexaenoic acid (DHA) and docosapentaenoic acid (DPAn-6) algal oils reduce inflammatory mediators in human peripheral mononuclear cells in vitro and paw edema in vivo. Lipids 2010, 45:375-384.